Loren David Walensky

Loren David Walensky, M.D., Ph.D.

Professor of Pediatrics

617-355-6369

Publications

Publications View

BH3-triggered structural reorganization drives the activation of proapoptotic BAX.

Authors: Authors: Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD.
Mol Cell 2010-11-12
View full abstract on Pubmed

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.

Authors: Authors: Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD.
Proc Natl Acad Sci U S A 2010-08-10
View full abstract on Pubmed

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.

Authors: Authors: Stewart ML, Fire E, Keating AE, Walensky LD.
Nat Chem Biol 2010-08-01
View full abstract on Pubmed

BAX activation is initiated at a novel interaction site.

Authors: Authors: Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD.
Nature 2008-10-23
View full abstract on Pubmed

Dual role of proapoptotic BAD in insulin secretion and beta cell survival.

Authors: Authors: Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, Datta SR, Pitter KL, Bird GH, Wikstrom JD, Deeney JT, Robertson K, Morash J, Kulkarni A, Neschen S, Kim S, Greenberg ME, Corkey BE, Shirihai OS, Shulman GI, Lowell BB, Korsmeyer SJ.
Nat Med 2008-02-01
View full abstract on Pubmed

Dissection of the BCL-2 family signaling network with stabilized alpha-helices of BCL-2 domains.

Authors: Authors: Pitter K, Bernal F, Labelle J, Walensky LD.
Methods Enzymol 2008-01-01
View full abstract on Pubmed

Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains.

Authors: Authors: Bird GH, Bernal F, Pitter K, Walensky LD.
Methods Enzymol 2008-01-01
View full abstract on Pubmed

The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.

Authors: Authors: Verdine GL, Walensky LD.
Clin Cancer Res 2007-12-15
View full abstract on Pubmed

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors: Authors: Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL.
J Am Chem Soc 2007-03-07
View full abstract on Pubmed

A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro.

Authors: Authors: Oh KJ, Barbuto S, Pitter K, Morash J, Walensky LD, Korsmeyer SJ.
J Biol Chem 2006-12-01
View full abstract on Pubmed